Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (September 2005)
52 slides from Anesiva's merger presentation, Sep 26, 2005
Slide 1: Corgentech and AlgoRx Announce Merger Agreement
Corgentech and AlgoRx Announce Merger Agreement Presentation to AlgoRx Employees September 26, 2005
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “pla
Slide 3: Forward Looking Statements (2)
FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involv
Slide 4: Creating Late-Stage Company
CREATING LATE-STAGE COMPANY Multiple late-stage product development programs focused on significant clinical problems Pain management Inflammatory diseases Brings together development and commercial expertise in critical areas Marketing, commercialization, regulatory affairs and clinical trials mana
Slide 5: Agenda
AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary
Slide 6: Corgentech
CORGENTECH Public biotechnology company founded in 1999 ~70 employees all based in South San Francisco Developing transcription factor decoys for inflammatory diseases and cancer and aptamers for antibiotic resistance Two Phase 1/2 trials under way for NF-kB Decoy for eczema Experience in marketing,
Slide 7: Accomplishments: Research and Development
ACCOMPLISHMENTS Research NF-kB Decoy lead compound in 6 months Demonstrated efficacy in multiple preclinical models of arthritis, asthma, IBD and eczema Developed internally topical formulation equivalent to best of Dow All IND-enabling preclinical studies for NF-kB Decoy for eczema accomplished int
Slide 8: Accomplishments: Regulatory
ACCOMPLISHMENTS Regulatory First drug with Fast Track status in CardioRenal Division In Phase 3 CABG trial, persuaded FDA to accept 2,400 patient trial w/graft failure surrogate endpoint and one year f/u in lieu of FDA proposal of 13,000 patient trial w/mortality clinical endpoint lasting several ye
Slide 9: Accomplishments: Manufacturing and Commercial
ACCOMPLISHMENTS Manufacturing Managed drug supply, and device design and supply Drug and device at commercial scale in mid-Phase 3 All validation batches were completed in 2004 Execution of long term supply agreements pending clinical data Commercial Separate ICD-9 code in May 2004 – “impossible bef
Slide 10: Accomplishments: BMS Deal
ACCOMPLISHMENTS BMS Deal $45 MM upfront 50/50 US profit split $570 MM milestone payments 12-20% ex-US royalties 65/35 expense split until commercialization Third best Phase 3 deal at time CGTK retained control and drove process to CGTK timeline, not longer BMS timeline
Slide 11: Accomplishments: Finance
ACCOMPLISHMENTS Finance Private Four up rounds of private financing A: $2.5 million with Spirit/Trinity Fund B: $13 million with Alta, InterWest, JP Morgan C: $80 million with Bear Stearns, HBM Ventures D: $20 million with BMS IPO S-1 filed in 23 days, not typical 6 weeks CFSB, Lehman, CIBC, Piper J
Slide 12: Diverse Team
‘9 DIVERSE TEAM CorcENTECH > Genentech >A runner nie Les, @ — & Bristol-Myers Squibb DaVita. ax @eCH rams
Slide 13: Agenda
AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary
Slide 14: Product Pipeline
PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALGRX 3268 Pre-procedural analgesia ALGRX 4975 Post-surgical pain Morton’s neuroma Tendonitis NF-kB Decoy Atopic dermatitis (eczema) ALGRX 1207 Cutaneous neuropathic pain
Slide 15: ALGRX 3268: Topical Local Anesthesia
ALGRX 3268- TOPICAL LOCAL ANESTHESIA Indication Reduction of pain associated with needlesticks for venipunctures and intravenous line placements Phase 3 trial underway Clinical data expected in second half of 2005 Key desirable product attributes Sterile, pre-filled, needle-free disposable delivery
Slide 16: ALGRX 3268: Reduction in Pain from Venipuncture
ALGRX 3268 Reduction in Pain from Venipuncture after Administration EMLA Package Insert for EMLA ALGRX 3268 VAS, mm -10 -20 -30 VAS, mm -10 -20 -30 3 60 Time after administration, minutes 1 3 5 Time after administration, minutes ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for
Slide 17: ALGRX 3268 Development
ALGRX 3268 DEVELOPMENT Protocol Age Group Phase Total Patients Primary Endpoint Status Primary Endpoint Antecubital Fossa Adults 1 272 Safety and Efficacy Achieved Primary Endpoint Back of Hand Adults 1 183 Safety and Efficacy Evaluate Circulating Achieved Primary Endpoint Pharmacokinetics Adults 1
Slide 18: ALGRX 4975 – VR1 Anesthetic
ALGRX 4975 – VR1 ANESTHETIC Capsaicin Overview Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does not affect other nerve fibers important for motor skills Activat
Slide 19: ALGRX 4975 Development
ALGRX 4975 DEVELOPMENT Protocol Phase Total Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery 2 40 Time to Rescue Medication Primary Endpoint Achieved Bunion Removal Surgery 2 182 Magnitude of Pain Relief Primary Endpoint Achieved Hernia Repair 2 48 Magnitude and Duration of
Slide 20: Common, Chronic Problem: Eczema
COMMON, CHRONIC PROBLEM Eczema (Atopic Dermatitis) Red, cracked, and unbearably itchy skin caused by excess inflammation in the skin Makes the person more susceptible to infection 90% of people with AD have staph bacteria on their skin compared to <5% of people without AD Affects about 15 million pe
Slide 21: Skin Is a Great Target
SKIN IS A GREAT TARGET Local Therapy Limited Systemic Exposure Systemic exposure (based on plasma levels of NF-kB Decoy) was undetectable in 4 week dermal study in minipigs (using CGTK’s PCR based assay, sensitivity = 1.2 ng/ml) Epidermis Dermis
Slide 22: Efficient Delivery to Pig Skin
EFFICIENT DELIVERY TO PIG SKIN NF-kB Decoy is Efficiently Delivered to Skin* Using “Non-Exotic” Formulation No Drug NF-kB Decoy Red Nuclear Stain + Green-Tagged Decoy = Yellow-green Nuclei *Pig skin generally accepted as the best model for human skin
Slide 23: Good Delivery of NF-kB Decoy to Human Dermis
GOOD DELIVERY OF NF-kB DECOY TO HUMAN DERMIS Drug penetration using novel Dow Pharma formulations were compared to CGTK formulations in human skin Single application of 0.5% NF-kB Decoy (radiolabeled) 0 . 8 0 0 . 7 0 0 . 6 0 0 . 5 0 0 . 4 0 % Dose Applied 0 . 3 0 0 . 2 0 0 . 1 0 0 . 0 0 Dow Formulat
Slide 24: NF-kB Decoy Treatment Blocks Inflammatory Genes
NF-kB DECOY TREATMENT BLOCKS INFLAMMATORY GENES RT- PCR Analysis of Gene Expression Following 2 weeks of Daily Decoy Treatment in Dust-mite Antigen Treatment Model % Reduction 40 NF-kB Decoy Betamethasone TNFa IL-1ß IL-4 IL-6 IFN-g CCR3
Slide 25: Rapid Onset and Lack of Rebound with NF-kB Decoy
RAPID ONSET AND LACK OF REBOUND WITH NF-kB DECOY Ear Swelling (Microns) 0 7 14 21 28 35 42 49 Start Daily Treatment Placebo Betamethasone NF-kB Decoy Stop Treatment Days
Slide 26: No Thinning of the Skin
NO THINNING OF THE SKIN Skin thickness measured following 3 days of treatment (2x per day) Ear Thickness (microns) Normal Beta- NF-KB Skin methasone Decoy Betamethasone treatment: Skin thinning Downregulation of key skin structural genes including MMP-9 Collagen I and III Tenascin C Elastin NF-kB Tr
Slide 27: Decreased Number and Size of Papillomas
DECREASED NUMBER AND SIZE OF PAPILLOMAS Tested chronic treatment with NF-kB Decoy in presence of DMBA/TPA (tumor promoter) DMBA + ACETONE DMBA + TPA DMBA + TPA + Tacrolimus DMBA + TPA + NF-kBD Papilloma
Slide 28: Drug Comparison
DRUG COMPARISON Topical Agents NF- kB Decoy Steroids Calcineurin Inhibitors Efficacy +++ +++ ++ Dosing Once a day or less Once/twice a day Short-term Twice a day Short-term/intermittent long-term Skin-thinning None Limits use None Onset of action +++ +++ ++ Systemic exposure Limited May cause signif
Slide 29: Phase 1/2s: Proof of Concept
PHASE 1/2’s: PROOF OF CONCEPT Adults with mild-moderate eczema 200 cm2 affected area (treated area will be moderate) Randomized, double blind Endpoints Safety, tolerability and PK Multiple endpoints to assess preliminary efficacy Physician and patient assessments of target area (signs and symptoms)
Slide 30: Phase 1/2s: Proof of Concept (2)
PHASE 1/2’s: PROOF OF CONCEPT (2) US Trial 75 patients 9 sites Four cohorts (BID) 0.25% 20 patients 0.50% 20 patients 1.00% 20 patients Placebo 15 patients Parallel dosing 21 days of treatment and 28 days of follow-up 57 enrolled patients Ex-US Trial 120 patients 9 sites (Switzerland and 8 in Austra
Slide 31: ALGRX 1207
ALGRX 1207 IND-enabling studies underway New chemical class of local anesthetic for topical analgesia Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including: Neuropathic pain Dermatological surgery Surgical incisions
Slide 32: ALGRX 1207 vs Lidocaine
ALGRX 1207 New local anesthetic allowing rapid and complete topical anesthesia without exotic delivery Percent complete anesthesia -120 -110 -100 -90 Time, minutes Percent complete anesthesia -120 -60 0 60 120 180 240 300 360 420 Time, minutes Lidocaine ALGRX 1207 Unique non-clinical results in rele
Slide 33: Prevalence of Pain in Seven Major Countries
PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES PATIENT NUMBERS (in thousands) Prevalence of post-operative pain 75,068 Prevalence of back pain 208,996 Prevalence of HIV and AIDS pain 847 Prevalence of diabetic neuropathy pain 13,243 Prevalence of osteoarthritic pain 46,610 Above indications are all tar
Slide 34: 3268: Topical Local Anesthesia Market Dynamics
3268: TOPICAL LOCAL ANESTHESIA MARKET DYNAMICS Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric hospitals and specialized pediatric departments in larger general hospitals Continuing pressure on cost reduction and patient through-put in hos
Slide 35: 3268: Needlestick/Venipuncture Marketplace in the U.S.
3268: NEEDLESTICK/VENIPUNCTURE MARKETPLACE IN THE U.S. 42M Pediatric in-hospital 315M Adult in-hospital 40M Hemodialysis visits 54K Pediatric physician offices 11K Outpatient care centers1 1.3K Blood donation centers1 At home self-administration market 1. 2001 US census
Slide 36: 3268: TLAs in Pediatric Hospital Settings
3268: TLAs IN PEDIATRIC HOSPITAL SETTINGS Relevant Pediatric Procedures Spinal Tap/ LPs 12% Chemotherapy 1% Surgery/ IV Insertions 12% IV Insertions 27% Blood Draws 48% 18 million procedures* Treated Relevant Procedures Spinal Tap/ LPs 11% Chemotherapy 3% Surgery/ IV Insertions 19% IV Insertions 35%
Slide 37: 3268: Current Clinical Practice of TLAs in Hospital Setting
3268: CURRENT CLINICAL PRACTICE OF TLAs IN HOSPITAL SETTING Many hospitals offer TLA agents as an option to reduce needlestick pain Existence of established protocols for TLA use is mixed Nurses rather than physicians usually decision maker Some ERs apply TLAs, however use is often impractical due t
Slide 38: 3268: Phased Marketing Approach
3268: PHASED MARKETING APPROACH Physcian Offices, Labs, Blood donation centers Hemodialysis Centers In-hospital Pediatric 18M
Slide 39: 4975: Post-Operative Pain Market
4975: POST-OPERATIVE PAIN MARKET US post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively 50% indicate lack of adequate pain control Patients’ post-surgical pain experiences between 1993 and 1999 have not improved Europe also under treats post
Slide 40: 4975: Potential Targets—High Volume Surgical Procedures
4975: POTENTIAL TARGETS—HIGH VOLUME SURGICAL PROCEDURES Procedure Volume Caesarean Section 1,163,893 Hysterectomy (all) 1,042,715 Episiotomy 417,699 Arthroplasty (knee) 399,139 Hip Replacement, 343,554 total/partial CABG 316,471 Colorectal resection 280,969
Slide 41: Current Post-Op Pain Medications vs. ALGRX 4975
CURRENT POST-OP PAIN MEDICATIONS VS. ALGRX 4975 Epidurals Use declining significantly due to contra-indication in combination use with anticoagulants Opioids Nausea, vomiting, respiratory depression and constipation Sedation may limit the ability of the patient to ambulate and prolong time to discha
Slide 42: NF-kB Decoy: Eczema Market
NF-kB DECOY: ECZEMA MARKET Eczema market is comprised of mild, moderate and severe patient segments within the pediatric and adult patient populations Patient Population Segmented by Mild, Moderate and Severe (US, EU, Japan) Severe 10% 5.2M 15.6M 31.1M Moderate 30% Mild 60% Sources: 1. International
Slide 43: NF-kB Decoy: Retail Rx Sales (U.S.)
NF-kB DECOY: RETAIL Rx SALES (U.S.) Total Dollars (millions) $900 $800 $700 $600 $500 $400 $300 $200 $100 $0 1999 2000 2001 2002 2003 2004 Corticosteroids Protopic Elidel Source: IMS Health, 2004
Slide 44: 1207: Target Market
1207: TARGET MARKET Deep, rapid penetration of the skin Long duration of action Addresses neuropathic pain market Non-exotic delivery Lidoderm® (Endo Pharmaceuticals) Postherpetic Neuralgia Indication ($ in millions) $45 (IMS) $107 (IMS) $215 (IMS) $300 2004E (Endo) $400 2005E (Endo)
Slide 45: Agenda
AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary
Slide 46: Terms of Merger Agreement
TERMS OF MERGER AGREEMENT Both Secaucus and South San Francisco facilities to remain open Headquarters: South San Francisco Combined management team will work to integrate the companies and to identify synergies, redundancies and needs across the combined organization Corgentech and AlgoRx currently
Slide 47: Projected Timetable
PROJECTED TIMETABLE Sept 23 Execute merger agreement Sept 26 Analyst call pre-market open from AlgoRx AlgoRx employee meeting in mid-morning Fly to SF Corgentech employee meeting in mid-afternoon October and thereafter Investor and analyst meetings Week of Oct 17 File S-4 with SEC
Slide 48: Projected Timetable (2)
PROJECTED TIMETABLE (2) Week of Nov 14 First round of SEC comments File first amendment to S-4 Week of Nov 21* Second round of SEC comments File second amendment Week of Dec 5* Record date Week of Jan 2, 06* Shareholder special meetings * These dates assume that the SEC seeks additional review of ou
Slide 49: Agenda
AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary
Slide 50: Communications
COMMUNICATIONS Identify key individual contacts in Secaucus, Sunnyvale and SSF to assure clear communication, answer questions, etc. during transition period Project teams Good venue to share information, discuss issues, solve problems, allocate resources Minutes within 36 hours – good means to upda
Slide 51: Agenda
AGENDA About Corgentech Product Pipeline of Combined Company Terms and Timelines Communications Summary
Slide 52: Strong Combined Company
STRONG COMBINED COMPANY Increased development resources (personnel and financial) assure timely execution of multiple clinical trials Additional regulatory, manufacturing and quality resources assure timely FDA submissions, increased likelihood of successful plant inspections needed for FDA approval
Algorx Pharmaceuticals — Merger or Acquisition (September 2005) on 6ix